Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease , respectively -


- Subcutaneous VRDN-003...

Related Keywords

Massachusetts ,United States ,Waltham ,California ,San Francisco ,Clearside Bio ,Barrett Katz ,Steve Mahoney ,Compensation Committee ,Viridian Therapeutics Inc ,Key Program Milestones ,Exchange Commission ,Nasdaq ,Viridian Therapeutics ,Chief Executive Officer ,Healthcare Conference ,Investigational New Drug Application ,Eye Disease Portfolio ,Fcrn Portfolio ,Thomas Ciulla ,Chief Medical Officer ,Chief Development Officer ,Inducement Grant ,Incentive Plan ,Nasdaq Listing Rule ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,